5-溴-4-氯-6-甲基嘧啶 | 3438-55-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-溴-4-氯-6-甲基嘧啶
• 中文别名: 4-甲基-5-溴-6-氯嘧啶
• 英文名称: 5-bromo-4-chloro-6-methylpyrimidine
• 英文别名: 5-bromo-4-chloro-6-methyl-pyrimidine；5-Brom-4-chlor-6-methyl pyrimidin；5-Brom-6-chlor-4-methyl-pyrimidin
• CAS: 3438-55-9
• 化学式: C₅H₄BrClN₂
• 分子量: 207.457
• InChiKey: COSNNPGRFRGVPC-UHFFFAOYSA-N

物化性质

• 熔点：
  55.0-55.5 °C
• 沸点：
  271.2±35.0 °C(Predicted)
• 密度：
  1.724±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Bromo-4-chloro-6-methylpyrimidine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Bromo-4-chloro-6-methylpyrimidine
CAS number: 3438-55-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H4BrClN2
Molecular weight: 207.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴-4-氯-6-甲基嘧啶 在 双氧水 、 三乙胺 、 对甲苯磺酰肼 、 molybdenum(VI) oxide 作用下， 以 氯仿 、 溶剂黄146 、 乙腈 为溶剂， 反应 32.0h， 生成 5-溴-4-甲基嘧啶-2-甲腈
  参考文献：
  名称：

  Yamanaka, Hiroshi; Sakamoto, Takao; Nishimura, Sumiko, Chemical and pharmaceutical bulletin, 1987, vol. 35, # 8, p. 3119 - 3126

  摘要：

  DOI：
• 作为产物：
  描述：

  5-溴-6-甲基嘧啶-4-醇 在 三氯氧磷 作用下， 反应 3.0h， 以91%的产率得到5-溴-4-氯-6-甲基嘧啶
  参考文献：
  名称：

  Scalable Synthesis of 4-Substituted 5-Bromo-6-methylpyrimidines

  摘要：

  小卤代杂芳环系统是有价值的单体，可以快速进入新颖且理想的化学空间，部分原因是它们能够参与已建立的交叉偶联化学，例如 Heck、Stille 和 Suzuki 反应。描述了一种实用的、可扩展的合成路线，用于构建多种 4-取代 5-溴-6-甲基嘧啶单体。

  DOI：

  10.1055/s-0030-1259976

文献信息

• [EN] TETRACYCLIC INHIBITORS OF JANUS KINASES<br/>[FR] INHIBITEURS TETRACYCLIQUES DE JANUS KINASES
  申请人：INCYTE CORP

  公开号：WO2005105814A1

  公开（公告）日：2005-11-10

  The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.

  本发明提供了能调节雅努斯激酶活性并且在治疗与雅努斯激酶活性相关的疾病方面有用的化合物，例如免疫相关疾病和癌症。
• [EN] HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS<br/>[FR] COMPOSÉS HÉTÉROAROMATIQUES ET LEUR UTILISATION COMME LIGANDS DE LA DOPAMINE D1
  申请人：PFIZER

  公开号：WO2014072881A1

  公开（公告）日：2014-05-15

  The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides thereof; processes and intermediates for preparation of; and compositions and uses thereof. The present invention further provides D1 agonists with reduced D1R desensitization, D1 agonists with a reduced β- arrestin recruitment activity relative to Dopamine, D1 agonists interacting significantly with the Ser188 but not significantly with the Ser202 of a D1R when binding to the D1R, D1 agonists interacting less strongly with the Asp103 and interacting less strongly with the Ser198 of a D1R when binding to the D1R, and their uses.

  本发明部分提供了化合物I的公式：及其药学上可接受的盐和N-氧化物；制备的过程和中间体；以及其组合物和用途。本发明进一步提供了具有减少D1R耐受性的D1激动剂，相对于多巴胺具有减少β-阿雷斯汀招募活性的D1激动剂，当结合到D1R时与D1R的Ser188显著相互作用但与Ser202的相互作用不显著的D1激动剂，当结合到D1R时与D1R的Asp103相互作用较弱并且与Ser198相互作用较弱的D1激动剂，以及它们的用途。
• HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS
  申请人：PFIZER INC.

  公开号：US20140128374A1

  公开（公告）日：2014-05-08

  The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides of the foregoing; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, salts or N-oxides, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, impulsivity, compulsive gambling, overeating, autism spectrum disorder, MCI, age-related cognitive decline, dementia, RLS, Parkinson's disease, Huntington's chorea, anxiety, depression, MDD, TRD, and bipolar disorder.

  本发明在一定程度上提供了以下式I的化合物：以及这些化合物的药用盐和其N-氧化物；用于制备这些化合物的工艺；用于制备中间体；以及含有这些化合物、盐或N-氧化物的组合物，并且它们用于治疗D1介导（或D1相关）的疾病，包括但不限于精神分裂症（例如其认知和消极症状）、认知障碍（例如与精神分裂症、阿尔茨海默病、帕金森病或药物治疗相关的认知障碍）、注意力缺陷多动障碍（ADHD）、冲动性、强迫性赌博、过度进食、自闭症谱系障碍、轻度认知障碍、年龄相关认知衰退、痴呆症、不宁腿综合征、帕金森病、亨廷顿舞蹈症、焦虑、抑郁症、抑郁障碍、难治性抑郁症和躁郁症。
• Suzuki-Miyaura and Negishi Approaches to a Series of Forensically Relevant Pyridines and Pyrimidines
  作者：Zbigniew Czarnocki、Dariusz Błachut、Joanna Szawkało

  DOI：10.1055/s-0030-1260224

  日期：2011.11

  ridines were prepared. The synthesis of 5-aryl-4-methylpyrimidines was accomplished by Suzuki­-Miyaura cross-coupling reaction between arylboronic acids and 5-bromo-4-methylpyrimidine. The 4-benzylpyrimidines and 2,6-benzylpyridines were synthesized by treatment of 4-bromopyrimidine and 2,6-dibromopyridine derivatives with ring-substituted benzylzinc reagents. cross-coupling reaction - amphetamine

  制备了5-芳基-4-甲基嘧啶，4-苄基嘧啶，2，6-苄基吡啶和2，6-二苄基-4-甲基吡啶的苯环取代的衍生物的文库。5-芳基-4-甲基嘧啶的合成是通过芳基硼酸与5-溴-4-甲基嘧啶之间的Suzuki-Miyaura交叉偶联反应完成的。通过用环取代的苄基锌试剂处理4-溴嘧啶和2,6-二溴吡啶衍生物来合成4-苄基嘧啶和2,6-苄基吡啶。 交叉偶联反应-苯丙胺类似物-Leuckart合成-药物-杂环
• Aminopyrimidine derivatives, processes for their preparation, and
  申请人：Sankyo Company, Limited

  公开号：US04435402A1

  公开（公告）日：1984-03-06

  Compounds having the formula (I) ##STR1## [wherein: R.sup.1 and R.sup.2 are each alkyl or halogen, or they are trimethylene or tetramethylene; R.sup.3 is hydrogen or alkyl; A is alkylene; and R.sup.4 is optionally substituted phenyloxy or benzyloxy substituted with at least one alkyl, halogen, alkoxy, alkylthio, alkenyl, trifluoromethyl or nitro; optionally substituted phenyl substituted with one or two halogen atoms, alkyl or alkoxy; furyl or thienyl] and their salts.

  具有以下式(I)的化合物 ##STR1## [其中：R.sup.1和R.sup.2分别为烷基或卤素，或它们为三亚甲基或四亚甲基；R.sup.3为氢或烷基；A为烷基；R.sup.4为可以被取代的苯氧基或苄氧基，取代基至少为一种烷基、卤素、烷氧基、烷基硫氧基、烯基、三氟甲基或硝基；可以被取代的苯基，取代基为一种或两种卤素原子、烷基或烷氧基；呋喃基或噻吩基]及其盐。